Drug pediatric vouchers can have heavy adult involvement, US FDA explains
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued a draft guidance to help drug sponsors assess whether they are eligible for a rare pediatric disease priority review voucher1.